LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Comparison analysis of FIB-4, LIVERFASt, LSM in Sequential and Combinatory Pathways for NAFLD
Comparison analysis of FIB-4, LIVERFASt, LSM in Sequential and Combinatory Pathways for NAFLD